<!DOCTYPE html>
<html lang="de">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Neurotransmitter-Defekte - Teil 1</title>
<style>
@import url('https://fonts.googleapis.com/css2?family=Inter:wght@300;400;500;600;700&display=swap');

* {
margin: 0;
padding: 0;
box-sizing: border-box;
}

:root {
--primary-color: #667eea;
--secondary-color: #764ba2;
--accent-color: #f093fb;
--success-color: #4facfe;
--warning-color: #fa709a;
--danger-color: #ff6b6b;
--info-color: #74b9ff;
--neuro-color: #9c88ff;
--dopamine-color: #ff6b9d;
--serotonin-color: #4ecdc4;
--text-primary: #2d3748;
--text-secondary: #4a5568;
--text-muted: #718096;
--bg-white: #ffffff;
--bg-light: #f8fafc;
--bg-lighter: #f1f5f9;
--border-radius: 16px;
--border-radius-lg: 24px;
--spacing-xs: 8px;
--spacing-sm: 16px;
--spacing-md: 24px;
--spacing-lg: 32px;
--spacing-xl: 48px;
--shadow-sm: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
--shadow-md: 0 10px 15px -3px rgba(0, 0, 0, 0.1);
--shadow-lg: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
}

body {
font-family: 'Inter', -apple-system, BlinkMacSystemFont, sans-serif;
line-height: 1.6;
color: var(--text-primary);
background: linear-gradient(135deg, #f8fafc 0%, #e2e8f0 100%);
min-height: 100vh;
}

.container {
max-width: 1400px;
margin: 0 auto;
padding: var(--spacing-md);
}

/* Header */
.header {
background: var(--bg-white);
border-radius: var(--border-radius-lg);
padding: var(--spacing-xl);
margin-bottom: var(--spacing-lg);
text-align: center;
box-shadow: var(--shadow-md);
border: 1px solid #e2e8f0;
}

.header h1 {
background: linear-gradient(135deg, var(--neuro-color), var(--dopamine-color), var(--serotonin-color));
background-size: 200% 200%;
-webkit-background-clip: text;
-webkit-text-fill-color: transparent;
background-clip: text;
font-size: clamp(2rem, 5vw, 3.5rem);
font-weight: 700;
margin-bottom: var(--spacing-sm);
animation: gradientShift 4s ease-in-out infinite;
}

@keyframes gradientShift {
0%, 100% { background-position: 0% 50%; }
50% { background-position: 100% 50%; }
}

.header p {
color: var(--text-secondary);
font-size: 1.3rem;
font-weight: 400;
}

/* Progress bar */
.progress-container {
background: var(--bg-lighter);
border-radius: 50px;
height: 10px;
margin-top: var(--spacing-md);
overflow: hidden;
}

.progress-fill {
background: linear-gradient(90deg, var(--neuro-color), var(--dopamine-color));
height: 100%;
border-radius: 50px;
transition: width 0.8s cubic-bezier(0.4, 0, 0.2, 1);
position: relative;
overflow: hidden;
}

.progress-fill::after {
content: '';
position: absolute;
top: 0;
left: 0;
width: 100%;
height: 100%;
background: linear-gradient(90deg, transparent, rgba(255, 255, 255, 0.3), transparent);
animation: progressShimmer 2s infinite;
}

@keyframes progressShimmer {
0% { transform: translateX(-100%); }
100% { transform: translateX(100%); }
}

/* Navigation */
.navigation {
background: var(--bg-white);
border-radius: var(--border-radius);
padding: var(--spacing-md);
margin-bottom: var(--spacing-lg);
display: flex;
flex-wrap: wrap;
gap: var(--spacing-sm);
justify-content: center;
box-shadow: var(--shadow-sm);
border: 1px solid #e2e8f0;
}

.nav-btn {
background: var(--bg-light);
border: 2px solid #e2e8f0;
color: var(--text-primary);
padding: 16px 24px;
border-radius: 50px;
cursor: pointer;
font-size: 14px;
font-weight: 600;
transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
text-transform: uppercase;
letter-spacing: 0.5px;
}

.nav-btn:hover {
transform: translateY(-2px);
box-shadow: var(--shadow-md);
background: var(--bg-white);
border-color: var(--neuro-color);
}

.nav-btn.active {
background: linear-gradient(135deg, var(--neuro-color), var(--dopamine-color));
color: white;
border-color: var(--neuro-color);
box-shadow: var(--shadow-md);
}

/* Content sections */
.content-section {
background: var(--bg-white);
border-radius: var(--border-radius-lg);
padding: var(--spacing-xl);
margin-bottom: var(--spacing-lg);
box-shadow: var(--shadow-md);
border: 1px solid #e2e8f0;
display: none;
}

.content-section.active {
display: block;
animation: slideInUp 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

@keyframes slideInUp {
from {
opacity: 0;
transform: translateY(20px);
}
to {
opacity: 1;
transform: translateY(0);
}
}

.section-title {
background: linear-gradient(135deg, var(--neuro-color), var(--dopamine-color));
-webkit-background-clip: text;
-webkit-text-fill-color: transparent;
background-clip: text;
font-size: 2.5rem;
font-weight: 700;
margin-bottom: var(--spacing-lg);
position: relative;
padding-bottom: var(--spacing-sm);
}

.section-title::after {
content: '';
position: absolute;
bottom: 0;
left: 0;
width: 60px;
height: 4px;
background: linear-gradient(135deg, var(--neuro-color), var(--dopamine-color));
border-radius: 2px;
animation: expandWidth 0.8s ease-out 0.3s both;
}

@keyframes expandWidth {
from { width: 0; }
to { width: 60px; }
}

/* Subsections */
.subsection {
margin-bottom: var(--spacing-lg);
padding: var(--spacing-lg);
background: var(--bg-light);
border-radius: var(--border-radius);
border: 1px solid #e2e8f0;
transition: all 0.3s ease;
}

.subsection:hover {
transform: translateY(-2px);
box-shadow: var(--shadow-md);
background: var(--bg-white);
}

.subsection h3 {
color: var(--text-primary);
margin-bottom: var(--spacing-md);
font-size: 1.5rem;
font-weight: 600;
display: flex;
align-items: center;
gap: var(--spacing-xs);
}

.subsection h3::before {
content: '';
width: 4px;
height: 24px;
background: linear-gradient(135deg, var(--neuro-color), var(--dopamine-color));
border-radius: 2px;
}

.subsection p {
color: var(--text-secondary);
margin-bottom: 1rem;
line-height: 1.7;
}

.subsection ul {
color: var(--text-secondary);
padding-left: 1.5rem;
}

.subsection li {
margin-bottom: 0.5rem;
}

/* Tables */
.clinical-table {
width: 100%;
border-collapse: separate;
border-spacing: 0;
margin: var(--spacing-md) 0;
background: var(--bg-white);
border-radius: var(--border-radius);
overflow: hidden;
box-shadow: var(--shadow-sm);
border: 1px solid #e2e8f0;
}

.clinical-table th {
background: linear-gradient(135deg, var(--neuro-color), var(--dopamine-color));
color: white;
padding: var(--spacing-md);
text-align: left;
font-weight: 600;
font-size: 0.95rem;
text-transform: uppercase;
letter-spacing: 0.5px;
}

.clinical-table td {
padding: var(--spacing-md);
border-bottom: 1px solid #f1f5f9;
transition: all 0.3s ease;
color: var(--text-primary);
}

.clinical-table tbody tr:hover {
background: #f8fafc;
}

.clinical-table tbody tr:last-child td {
border-bottom: none;
}

/* Pathway diagrams */
.pathway-diagram {
background: var(--bg-white);
border: 2px solid var(--neuro-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
box-shadow: var(--shadow-sm);
}

.pathway-diagram h4 {
color: var(--text-primary);
margin-bottom: var(--spacing-md);
font-size: 1.3rem;
font-weight: 600;
text-align: center;
}

.pathway-diagram h5 {
color: var(--text-primary);
margin-bottom: var(--spacing-sm);
font-weight: 600;
}

.pathway-diagram p {
color: var(--text-secondary);
}

/* Neurotransmitter boxes */
.nt-box {
display: inline-block;
padding: 12px 20px;
margin: 6px;
border-radius: 12px;
font-weight: 600;
transition: all 0.3s ease;
box-shadow: var(--shadow-sm);
}

.nt-box:hover {
transform: translateY(-2px) scale(1.05);
box-shadow: var(--shadow-md);
}

.nt-box.dopamine {
background: linear-gradient(135deg, var(--dopamine-color), #ff7675);
color: white;
}

.nt-box.serotonin {
background: linear-gradient(135deg, var(--serotonin-color), #00b894);
color: white;
}

.nt-box.noradrenaline {
background: linear-gradient(135deg, #fd79a8, #e17055);
color: white;
}

.nt-box.bh4 {
background: linear-gradient(135deg, var(--warning-color), #fdcb6e);
color: white;
}

.nt-box.defect {
background: linear-gradient(135deg, var(--danger-color), #d63031);
color: white;
animation: pulseGlow 2s infinite;
}

@keyframes pulseGlow {
0%, 100% {
transform: scale(1);
box-shadow: var(--shadow-sm);
}
50% {
transform: scale(1.02);
box-shadow: var(--shadow-md);
}
}

.arrow {
display: inline-block;
margin: 0 var(--spacing-sm);
font-size: 1.8rem;
color: var(--neuro-color);
transition: all 0.3s ease;
}

.arrow:hover {
transform: scale(1.2);
color: var(--dopamine-color);
}

/* Highlight boxes */
.highlight-box {
background: linear-gradient(135deg, #fff7ed, #fed7aa);
border: 2px solid var(--warning-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
position: relative;
box-shadow: var(--shadow-sm);
}

.highlight-box::before {
content: '‚ö†Ô∏è';
position: absolute;
top: -12px;
left: 24px;
background: linear-gradient(135deg, var(--warning-color), #fee140);
padding: 8px 12px;
border-radius: 50%;
font-size: 1.2rem;
box-shadow: var(--shadow-sm);
}

.highlight-box h4 {
color: #92400e;
margin-bottom: var(--spacing-sm);
margin-top: var(--spacing-sm);
font-weight: 600;
}

.highlight-box p, .highlight-box ul, .highlight-box li {
color: #92400e;
}

/* Case study boxes */
.case-study {
background: linear-gradient(135deg, #f0fdf4, #dcfce7);
border: 2px solid var(--success-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
box-shadow: var(--shadow-sm);
}

.case-study h4 {
color: #166534;
margin-bottom: var(--spacing-md);
font-size: 1.3rem;
font-weight: 600;
display: flex;
align-items: center;
gap: var(--spacing-xs);
}

.case-study p, .case-study ul, .case-study li {
color: #166534;
}

/* Special neurotransmitter pathway boxes */
.neuro-pathway {
background: linear-gradient(135deg, #f3e8ff, #e9d5ff);
border: 2px solid var(--neuro-color);
border-radius: var(--border-radius);
padding: var(--spacing-lg);
margin: var(--spacing-md) 0;
box-shadow: var(--shadow-sm);
}

.neuro-pathway h4 {
color: #6b21a8;
margin-bottom: var(--spacing-md);
font-size: 1.3rem;
font-weight: 600;
}

.neuro-pathway p, .neuro-pathway ul, .neuro-pathway li {
color: #6b21a8;
}

/* Buttons */
.next-step {
text-align: center;
margin-top: var(--spacing-xl);
}

.next-btn {
background: linear-gradient(135deg, var(--neuro-color), var(--dopamine-color));
color: white;
border: none;
padding: 18px 36px;
border-radius: 50px;
cursor: pointer;
font-size: 16px;
font-weight: 600;
transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
box-shadow: var(--shadow-md);
text-transform: uppercase;
letter-spacing: 1px;
}

.next-btn:hover {
transform: translateY(-4px) scale(1.05);
box-shadow: var(--shadow-lg);
}

.part-info {
background: linear-gradient(135deg, #eff6ff, #dbeafe);
border: 2px solid var(--info-color);
border-radius: var(--border-radius);
padding: var(--spacing-md);
margin-bottom: var(--spacing-lg);
text-align: center;
box-shadow: var(--shadow-sm);
}

.part-info h3 {
color: var(--info-color);
margin-bottom: var(--spacing-sm);
}

.part-info p {
color: var(--text-secondary);
}

/* Responsive design */
@media (max-width: 768px) {
.container {
padding: var(--spacing-sm);
}

.header h1 {
font-size: 2.5rem;
}

.header p {
font-size: 1.1rem;
}

.navigation {
flex-direction: column;
}

.nav-btn {
width: 100%;
text-align: center;
}

.content-section {
padding: var(--spacing-md);
}

.section-title {
font-size: 2rem;
}

.subsection {
padding: var(--spacing-md);
}
}

@media (max-width: 480px) {
.header {
padding: var(--spacing-md);
}

.header h1 {
font-size: 2rem;
}

.section-title {
font-size: 1.8rem;
}
}

/* Animation stagger */
.subsection {
animation: fadeInStagger 0.6s ease-out both;
}

@keyframes fadeInStagger {
from {
opacity: 0;
transform: translateY(20px);
}
to {
opacity: 1;
transform: translateY(0);
}
}

.subsection:nth-child(1) { animation-delay: 0.1s; }
.subsection:nth-child(2) { animation-delay: 0.2s; }
.subsection:nth-child(3) { animation-delay: 0.3s; }
.subsection:nth-child(4) { animation-delay: 0.4s; }
.subsection:nth-child(5) { animation-delay: 0.5s; }
.subsection:nth-child(6) { animation-delay: 0.6s; }
.subsection:nth-child(7) { animation-delay: 0.7s; }
.subsection:nth-child(8) { animation-delay: 0.8s; }

</style>
</head>
<body>

<div class="container">

<div class="header">
<h1>üß† Neurotransmitter-Defekte</h1>
<p>Teil 1: Grundlagen, Biochemie & Klinisches Bild</p>
<div class="progress-container">
<div class="progress-fill" id="progressBar" style="width: 0%"></div>
</div>
</div>

<div class="part-info">
<h3>üìö Lerneinheit Teil 1</h3>
<p>Dieser erste Teil behandelt die biochemischen Grundlagen, Pathophysiologie und klinischen Pr√§sentationen der wichtigsten Neurotransmitter-Defekte.</p>
</div>

<div class="navigation">
<button class="nav-btn active" onclick="showSection('grundlagen')">1. Grundlagen</button>
<button class="nav-btn" onclick="showSection('biochemie')">2. Biochemie</button>
<button class="nav-btn" onclick="showSection('klinik')">3. Klinisches Bild</button>
</div>

<!-- Grundlagen -->
<div class="content-section active" id="grundlagen">
<h2 class="section-title">üéØ Grundlagen der Neurotransmitter-Defekte</h2>

<div class="subsection">
<h3>Definition und √úberblick</h3>
<p>Neurotransmitter-Defekte sind seltene angeborene Stoffwechselst√∂rungen, die die Biosynthese, den Abbau oder den Transport von Neurotransmittern betreffen. Sie f√ºhren zu schweren neurologischen Symptomen bereits im S√§uglingsalter.</p>

<div class="highlight-box">
<h4>Drei Hauptgruppen</h4>
<ul>
<li><strong>AADC-Mangel</strong> - Aromantische L-Aminos√§ure-Decarboxylase</li>
<li><strong>Tyrosinhydroxylase-Mangel</strong> - Geschwindigkeitsbestimmender Schritt</li>
<li><strong>BH4-Defekte</strong> - Tetrahydrobiopterin-Cofaktor-M√§ngel</li>
</ul>
</div>

<div class="neuro-pathway">
<h4>üß¨ Gemeinsame Charakteristika</h4>
<ul>
<li><strong>Autosomal-rezessive Vererbung</strong> (Ausnahme: GTP-CH-I auch dominant)</li>
<li><strong>Fr√ºhe Manifestation</strong> meist in den ersten Lebensmonaten</li>
<li><strong>Progressive Neurodegeneration</strong> ohne Behandlung</li>
<li><strong>Multisystemische Beteiligung</strong> m√∂glich</li>
<li><strong>Therapierbar</strong> bei fr√ºhzeitiger Diagnose</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Epidemiologie und Vererbung</h3>

<table class="clinical-table">
<thead>
<tr>
<th>Defekt</th>
<th>Inzidenz</th>
<th>Vererbung</th>
<th>Gen(e)</th>
<th>Chromosom</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AADC-Mangel</strong></td>
<td>~1:1.000.000</td>
<td>autosomal-rezessiv</td>
<td>DDC</td>
<td>7p12.2</td>
</tr>
<tr>
<td><strong>TH-Mangel</strong></td>
<td>~1:2.000.000</td>
<td>autosomal-rezessiv</td>
<td>TH</td>
<td>11p15.5</td>
</tr>
<tr>
<td><strong>GTP-CH-I</strong></td>
<td>1:1.000.000</td>
<td>AR + AD</td>
<td>GCH1</td>
<td>14q22.1-q22.2</td>
</tr>
<tr>
<td><strong>PTPS-Mangel</strong></td>
<td>1:5.000.000</td>
<td>autosomal-rezessiv</td>
<td>PTS</td>
<td>11q22.3-q23.3</td>
</tr>
<tr>
<td><strong>DHPR-Mangel</strong></td>
<td>1:1.000.000</td>
<td>autosomal-rezessiv</td>
<td>QDPR</td>
<td>4p15.3</td>
</tr>
<tr>
<td><strong>PCD-Mangel</strong></td>
<td>sehr selten</td>
<td>autosomal-rezessiv</td>
<td>PCBD1</td>
<td>10q22.1</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>Pathophysiologische Grundprinzipien</h3>

<div class="pathway-diagram">
<h4>Drei Hauptmechanismen der Krankheitsentstehung</h4>

<div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 20px 0;">

<div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fef2f2, #fecaca); border-radius: 12px; border: 2px solid #ef4444;">
<h5 style="color: #dc2626; margin-bottom: 15px;">üß† Neurotransmitter-Depletion</h5>
<p style="color: #dc2626;">Verminderte Synthese</p>
<div class="arrow" style="color: #dc2626;">‚Üì</div>
<p style="color: #dc2626;">Neurologische Symptome</p>
</div>

<div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #fff7ed, #fed7aa); border-radius: 12px; border: 2px solid #f97316;">
<h5 style="color: #ea580c; margin-bottom: 15px;">‚ö° Toxische Akkumulation</h5>
<p style="color: #ea580c;">Substrat-Anh√§ufung</p>
<div class="arrow" style="color: #ea580c;">‚Üì</div>
<p style="color: #ea580c;">Zellul√§re Dysfunktion</p>
</div>

<div style="text-align: center; padding: 20px; background: linear-gradient(135deg, #f0fdf4, #dcfce7); border-radius: 12px; border: 2px solid #22c55e;">
<h5 style="color: #16a34a; margin-bottom: 15px;">üîÑ Kompensatorische St√∂rungen</h5>
<p style="color: #16a34a;">Alternative Stoffwechselwege</p>
<div class="arrow" style="color: #16a34a;">‚Üì</div>
<p style="color: #16a34a;">Sekund√§re Effekte</p>
</div>

</div>
</div>

<div class="case-study">
<h4>üí° Zentrale Konzepte verstehen</h4>
<p><strong>Neurotransmitter-Hom√∂ostase:</strong> Das Gleichgewicht zwischen Synthese, Speicherung, Freisetzung, Wiederaufnahme und Abbau bestimmt die synaptische Funktion.</p>

<p><strong>Entwicklungsabh√§ngigkeit:</strong> Neurotransmitter sind essentiell f√ºr die normale Gehirnentwicklung - Defekte f√ºhren zu progressiven Sch√§den.</p>

<p><strong>Therapeutisches Fenster:</strong> Fr√ºhe Behandlung kann Neurodegeneration verhindern oder verlangsamen.</p>
</div>
</div>

<div class="subsection">
<h3>Neurotransmitter-Klassifikation</h3>

<div class="pathway-diagram">
<h4>Hauptgruppen der betroffenen Neurotransmitter</h4>

<div style="display: grid; grid-template-columns: 1fr 1fr; gap: 30px; margin: 20px 0;">

<div>
<h5 style="color: #dc2626; margin-bottom: 15px;">üî¥ Katecholamine</h5>
<div class="nt-box dopamine">Dopamin</div>
<div class="nt-box noradrenaline">Noradrenalin</div>
<div class="nt-box noradrenaline">Adrenalin</div>
<p style="margin-top: 10px; font-size: 0.9em;">‚Üí Motorik, Kognition, autonome Funktion</p>
</div>

<div>
<h5 style="color: #16a34a; margin-bottom: 15px;">üü¢ Indolamine</h5>
<div class="nt-box serotonin">Serotonin (5-HT)</div>
<div class="nt-box serotonin">Melatonin</div>
<p style="margin-top: 10px; font-size: 0.9em;">‚Üí Stimmung, Schlaf, Verhalten</p>
</div>

</div>

<div style="text-align: center; margin-top: 20px;">
<h5 style="color: #ea580c; margin-bottom: 15px;">üü° Wichtiger Cofaktor</h5>
<div class="nt-box bh4">Tetrahydrobiopterin (BH4)</div>
<p style="margin-top: 10px; font-size: 0.9em;">‚Üí Cofaktor f√ºr Tyrosin- und Tryptophanhydroxylase</p>
</div>

</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('biochemie')">Weiter zur Biochemie ‚Üí</button>
</div>
</div>

<!-- Biochemie -->
<div class="content-section" id="biochemie">
<h2 class="section-title">‚öóÔ∏è Biochemische Grundlagen</h2>

<div class="subsection">
<h3>1. Neurotransmitter-Biosynthese im Detail</h3>

<div class="pathway-diagram">
<h4>Der komplette Katecholamin-Biosyntheseweg</h4>

<div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="nt-box" style="background: linear-gradient(135deg, #6b7280, #4b5563); color: white;">L-Phenylalanin</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #059669, #047857); color: white;">Phenylalaninhydroxylase + BH4</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9); color: white;">L-Tyrosin</div>
</div>

<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 1: Tyrosin-Bildung (nicht bei NT-Defekten betroffen)</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="nt-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9); color: white;">L-Tyrosin</div>
<span class="arrow">‚Üí</span>
<div class="nt-box defect">Tyrosinhydroxylase + BH4</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #0891b2, #0e7490); color: white;">L-DOPA</div>
</div>

<div style="font-size: 0.9em; color: #dc2626; text-align: center; font-weight: bold;">Schritt 2: Geschwindigkeitsbestimmend! TH-Mangel hier</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="nt-box" style="background: linear-gradient(135deg, #0891b2, #0e7490); color: white;">L-DOPA</div>
<span class="arrow">‚Üí</span>
<div class="nt-box defect">AADC (+ PLP)</div>
<span class="arrow">‚Üí</span>
<div class="nt-box dopamine">Dopamin</div>
</div>

<div style="font-size: 0.9em; color: #dc2626; text-align: center; font-weight: bold;">Schritt 3: AADC-Mangel hier</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="nt-box dopamine">Dopamin</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #16a34a, #15803d); color: white;">DBH (+ Vitamin C)</div>
<span class="arrow">‚Üí</span>
<div class="nt-box noradrenaline">Noradrenalin</div>
</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="nt-box noradrenaline">Noradrenalin</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c); color: white;">PNMT</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #7c2d12, #92400e); color: white;">Adrenalin</div>
</div>

</div>
</div>

<div class="highlight-box">
<h4>Kritische biochemische Details</h4>
<p><strong>Tyrosinhydroxylase (TH):</strong></p>
<ul>
<li>Rate-limiting enzyme der Katecholamin-Synthese</li>
<li>Ben√∂tigt BH4 als Cofaktor</li>
<li>Feedback-Inhibition durch Dopamin</li>
<li>Temperaturempfindlich, daher Fluktuation der Symptome</li>
</ul>

<p><strong>AADC (Aromatische L-Aminos√§ure-Decarboxylase):</strong></p>
<ul>
<li>Wandelt L-DOPA in Dopamin um</li>
<li>Ben√∂tigt Pyridoxalphosphat (Vitamin B6) als Cofaktor</li>
<li>Katalysiert auch Tryptophan ‚Üí 5-HTP ‚Üí Serotonin</li>
<li>Beide Neurotransmitter-Systeme betroffen!</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>2. Serotonin-Biosyntheseweg</h3>

<div class="pathway-diagram">
<h4>Parallelweg zur Serotonin-Synthese</h4>

<div style="display: flex; flex-direction: column; align-items: center; gap: 15px; margin: 20px 0;">

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="nt-box" style="background: linear-gradient(135deg, #6b7280, #4b5563); color: white;">L-Tryptophan</div>
<span class="arrow">‚Üí</span>
<div class="nt-box bh4">Tryptophanhydroxylase + BH4</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #a855f7, #9333ea); color: white;">5-Hydroxytryptophan</div>
</div>

<div style="font-size: 0.9em; color: #6b7280; text-align: center;">Schritt 1: BH4-abh√§ngiger Schritt</div>

<div style="display: flex; align-items: center; gap: 10px; flex-wrap: wrap; justify-content: center;">
<div class="nt-box" style="background: linear-gradient(135deg, #a855f7, #9333ea); color: white;">5-HTP</div>
<span class="arrow">‚Üí</span>
<div class="nt-box defect">AADC (+ PLP)</div>
<span class="arrow">‚Üí</span>
<div class="nt-box serotonin">Serotonin (5-HT)</div>
</div>

<div style="font-size: 0.9em; color: #dc2626; text-align: center; font-weight: bold;">Schritt 2: Auch AADC-abh√§ngig!</div>

</div>

<div class="neuro-pathway">
<h4>üß† Warum AADC so kritisch ist</h4>
<p><strong>Doppelter Neurotransmitter-Block:</strong></p>
<ul>
<li><strong>Dopamin-Depletion:</strong> L-DOPA kann nicht zu Dopamin umgewandelt werden</li>
<li><strong>Serotonin-Depletion:</strong> 5-HTP kann nicht zu Serotonin umgewandelt werden</li>
<li><strong>Substrat-Akkumulation:</strong> L-DOPA und 5-HTP h√§ufen sich an</li>
<li><strong>Kompensation unm√∂glich:</strong> Kein alternativer Syntheseweg verf√ºgbar</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>3. Tetrahydrobiopterin (BH4) - Der entscheidende Cofaktor</h3>

<div class="pathway-diagram">
<h4>BH4-Metabolismus und Recycling</h4>

<div style="background: linear-gradient(90deg, #fef3c7 0%, #fde68a 50%, #f59e0b 100%); padding: 20px; border-radius: 10px; margin: 20px 0;">

<div style="text-align: center; margin-bottom: 20px;">
<h5 style="color: #92400e;">De-novo Biosynthese</h5>
</div>

<div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
<div class="nt-box" style="background: linear-gradient(135deg, #6b7280, #4b5563);">GTP</div>
<span class="arrow">‚Üí</span>
<div class="nt-box defect" style="font-size: 0.8em;">GTP-CH-I</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9);">7,8-Dihydroneopterin-TP</div>
</div>

<div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
<div class="nt-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9);">Dihydroneopterin-TP</div>
<span class="arrow">‚Üí</span>
<div class="nt-box defect" style="font-size: 0.8em;">PTPS</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #059669, #047857);">6-Pyruvoyl-BH4</div>
</div>

<div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
<div class="nt-box" style="background: linear-gradient(135deg, #059669, #047857);">6-Pyruvoyl-BH4</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #dc2626, #b91c1c);">Sepiapterin-Red.</div>
<span class="arrow">‚Üí</span>
<div class="nt-box bh4">BH4</div>
</div>

<div style="text-align: center; margin: 25px 0;">
<h5 style="color: #92400e;">Cofaktor-Funktion & Recycling</h5>
</div>

<div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
<div class="nt-box bh4">BH4</div>
<span style="margin: 0 10px; color: #92400e; font-weight: bold;">+</span>
<div class="nt-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9);">Tyrosin</div>
<span class="arrow">‚Üí</span>
<div class="nt-box" style="background: linear-gradient(135deg, #ef4444, #dc2626);">BH2 (oxidiert)</div>
<span style="margin: 0 10px; color: #92400e; font-weight: bold;">+</span>
<div class="nt-box" style="background: linear-gradient(135deg, #0891b2, #0e7490);">L-DOPA</div>
</div>

<div style="display: flex; align-items: center; justify-content: center; margin: 15px 0; flex-wrap: wrap; gap: 10px;">
<div class="nt-box" style="background: linear-gradient(135deg, #ef4444, #dc2626);">BH2</div>
<span class="arrow">‚Üí</span>
<div class="nt-box defect" style="font-size: 0.8em;">DHPR</div>
<span class="arrow">‚Üí</span>
<div class="nt-box bh4">BH4 (regeneriert)</div>
</div>

<div style="text-align: center; margin: 15px 0;">
<span class="arrow" style="transform: rotate(90deg); color: #92400e;">‚Üì</span><br>
<div class="nt-box" style="background: linear-gradient(135deg, #16a34a, #15803d);">Recycling-Zyklus</div>
</div>

</div>
</div>

<div class="case-study">
<h4>üîÑ BH4-Defekte - F√ºnf verschiedene Enzymdefekte</h4>

<p><strong>1. GTP-Cyclohydrolase I (GCH1):</strong></p>
<ul>
<li>Erster Schritt der BH4-Biosynthese</li>
<li>Autosomal-dominant (DYT5/Segawa) oder rezessiv</li>
<li>Komplette BH4-Depletion bei schweren Formen</li>
</ul>

<p><strong>2. 6-Pyruvoyl-tetrahydropterin-Synthase (PTPS):</strong></p>
<ul>
<li>H√§ufigster BH4-Defekt (60% aller F√§lle)</li>
<li>Akkumulation von Neopterin</li>
<li>Variable Schweregrade m√∂glich</li>
</ul>

<p><strong>3. Dihydropterinreduktase (DHPR):</strong></p>
<ul>
<li>Recycling-Defekt</li>
<li>Zus√§tzlich Fols√§ure-Metabolismus gest√∂rt</li>
<li>Schwerste Form der BH4-Defekte</li>
</ul>

<p><strong>4. Pterin-4Œ±-carbinolamin-Dehydratase (PCD):</strong></p>
<ul>
<li>Sehr seltener Recycling-Defekt</li>
<li>Primacapterin-Akkumulation</li>
<li>Meist mildere Verl√§ufe</li>
</ul>

<p><strong>5. Sepiapterin-Reduktase (SR):</strong></p>
<ul>
<li>Letzter Schritt der BH4-Synthese</li>
<li>L-DOPA-responsive Dystonie</li>
<li>Erhaltene Serotonin-Synthese</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>4. Neurotransmitter-Abbau und Clearance</h3>

<div class="pathway-diagram">
<h4>Dopamin- und Serotonin-Abbau</h4>

<div style="display: grid; grid-template-columns: 1fr 1fr; gap: 30px; margin: 20px 0;">

<div style="background: linear-gradient(135deg, #fef2f2, #fee2e2); padding: 15px; border-radius: 8px; border: 2px solid #fca5a5;">
<h5 style="color: #dc2626; margin-bottom: 10px;">üî¥ Dopamin-Abbau</h5>

<div style="text-align: center; margin: 10px 0;">
<div class="nt-box dopamine" style="font-size: 0.9em;">Dopamin</div>
</div>

<div style="display: flex; justify-content: space-around; margin: 15px 0;">
<div style="text-align: center;">
<div class="nt-box" style="background: linear-gradient(135deg, #059669, #047857); font-size: 0.8em;">COMT</div>
<div style="margin: 5px 0; font-size: 0.8em; color: #dc2626;">‚Üì</div>
<div style="background: #fde2e2; padding: 5px; border-radius: 5px; font-size: 0.8em; color: #dc2626;">3-MT</div>
</div>

<div style="text-align: center;">
<div class="nt-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9); font-size: 0.8em;">MAO</div>
<div style="margin: 5px 0; font-size: 0.8em; color: #dc2626;">‚Üì</div>
<div style="background: #fde2e2; padding: 5px; border-radius: 5px; font-size: 0.8em; color: #dc2626;">DOPAC</div>
</div>
</div>

<div style="text-align: center; margin: 15px 0;">
<div style="background: #fca5a5; padding: 8px; border-radius: 5px; font-size: 0.9em; color: white; font-weight: bold;">HVA</div>
<div style="font-size: 0.8em; color: #dc2626; margin-top: 5px;">Hauptmetabolit (Urin)</div>
</div>
</div>

<div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 15px; border-radius: 8px; border: 2px solid #86efac;">
<h5 style="color: #16a34a; margin-bottom: 10px;">üü¢ Serotonin-Abbau</h5>

<div style="text-align: center; margin: 10px 0;">
<div class="nt-box serotonin" style="font-size: 0.9em;">Serotonin</div>
</div>

<div style="text-align: center; margin: 15px 0;">
<div class="nt-box" style="background: linear-gradient(135deg, #7c3aed, #6d28d9); font-size: 0.8em;">MAO-A</div>
<div style="margin: 5px 0; font-size: 0.8em; color: #16a34a;">‚Üì</div>
<div style="background: #dcfce7; padding: 5px; border-radius: 5px; font-size: 0.8em; color: #16a34a;">5-HIAA</div>
</div>

<div style="text-align: center; margin: 15px 0;">
<div style="background: #22c55e; padding: 8px; border-radius: 5px; font-size: 0.9em; color: white; font-weight: bold;">5-HIAA (Urin)</div>
<div style="font-size: 0.8em; color: #16a34a; margin-top: 5px;">Diagnostischer Marker</div>
</div>
</div>

</div>
</div>

<div class="highlight-box">
<h4>üî¨ Diagnostische Bedeutung der Metabolite</h4>

<p><strong>Bei AADC-Mangel:</strong></p>
<ul>
<li><strong>‚Üë‚Üë L-DOPA im Plasma</strong> (kann nicht zu Dopamin umgewandelt werden)</li>
<li><strong>‚Üë‚Üë 5-HTP im Plasma</strong> (kann nicht zu Serotonin umgewandelt werden)</li>
<li><strong>‚Üì‚Üì HVA im Urin</strong> (kein Dopamin ‚Üí kein HVA)</li>
<li><strong>‚Üì‚Üì 5-HIAA im Urin</strong> (kein Serotonin ‚Üí kein 5-HIAA)</li>
<li><strong>‚Üë 3-OMD im Urin</strong> (alternatives L-DOPA-Abbauprodukt)</li>
</ul>

<p><strong>Bei TH-Mangel:</strong></p>
<ul>
<li><strong>‚Üì‚Üì L-DOPA im Plasma</strong> (verminderte Synthese)</li>
<li><strong>‚Üì‚Üì HVA im Urin</strong> (konsekutiv weniger Dopamin)</li>
<li><strong>Normal: 5-HTP und 5-HIAA</strong> (Serotonin-Weg intakt)</li>
</ul>

<p><strong>Bei BH4-Defekten:</strong></p>
<ul>
<li><strong>‚Üë‚Üë Phenylalanin im Plasma</strong> (wie bei PKU)</li>
<li><strong>‚Üì‚Üì HVA und 5-HIAA im Urin</strong> (beide Wege betroffen)</li>
<li><strong>Abnorme Pterin-Metabolite</strong> (spezifisch f√ºr den Defekt)</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>5. Neurotransmitter-Regulation und Feedback</h3>

<div class="neuro-pathway">
<h4>üéõÔ∏è Komplexe Regulationsmechanismen</h4>

<p><strong>Tyrosinhydroxylase-Regulation:</strong></p>
<ul>
<li><strong>Produkthemmung:</strong> Dopamin hemmt TH (negative R√ºckkopplung)</li>
<li><strong>Phosphorylierung:</strong> Aktivierung durch cAMP-abh√§ngige Proteinkinase</li>
<li><strong>Temperaturempfindlichkeit:</strong> Aktivit√§t ‚Üì bei Fieber</li>
<li><strong>Cofaktor-Verf√ºgbarkeit:</strong> BH4-Mangel = TH-Inhibition</li>
</ul>

<p><strong>AADC-Regulation:</strong></p>
<ul>
<li><strong>Substrat-Konkurrenz:</strong> L-DOPA vs. 5-HTP um dasselbe Enzym</li>
<li><strong>Vitamin B6-Abh√§ngigkeit:</strong> PLP als prosthetische Gruppe</li>
<li><strong>Gewebe-spezifische Expression:</strong> ZNS vs. Peripherie</li>
</ul>

<p><strong>Pr√§synaptische Kontrolle:</strong></p>
<ul>
<li><strong>Autorezepto-Feedback:</strong> D2-Rezeptoren hemmen weitere Dopamin-Freisetzung</li>
<li><strong>Wiederaufnahme:</strong> DAT und SERT kontrollieren synaptische Konzentrationen</li>
<li><strong>Vesicul√§re Speicherung:</strong> VMAT2 f√ºr beide Neurotransmitter-Systeme</li>
</ul>
</div>

<div class="case-study">
<h4>üí≠ Warum diese Regulationen klinisch relevant sind</h4>

<p><strong>Fluktuation der Symptome verstehen:</strong></p>
<ul>
<li><strong>Tageszeitliche Schwankungen:</strong> Tyrosinhydroxylase-Aktivit√§t variiert</li>
<li><strong>Fieber-induzierte Verschlechterung:</strong> TH-Hemmung bei erh√∂hter Temperatur</li>
<li><strong>Stress-Ausl√∂sung:</strong> Erh√∂hter Neurotransmitter-Verbrauch</li>
</ul>

<p><strong>Therapeutische Implikationen:</strong></p>
<ul>
<li><strong>L-DOPA-Dosierung:</strong> Muss Regulationsmechanismen ber√ºcksichtigen</li>
<li><strong>Carbidopa-Kombination:</strong> Verhindert periphere AADC-Aktivit√§t</li>
<li><strong>Timing der Medikation:</strong> Pharmacokinetik und -dynamik abstimmen</li>
</ul>
</div>
</div>

<div class="next-step">
<button class="next-btn" onclick="showSection('klinik')">Zum klinischen Bild ‚Üí</button>
</div>
</div>

<!-- Klinisches Bild -->
<div class="content-section" id="klinik">
<h2 class="section-title">üè• Klinisches Bild</h2>

<div class="subsection">
<h3>AADC-Mangel - Schwerste Form</h3>

<div class="case-study">
<h4>üìã Typischer Verlauf</h4>
<p><strong>Manifestationsalter:</strong> Meist erste Lebenswochen bis -monate</p>
<p><strong>Fr√ºheste Zeichen:</strong> Hypotonie, schwache Reflexe, Trinkschw√§che</p>
<p><strong>Progression:</strong> Ohne Behandlung schwere psychomotorische Retardierung</p>

<p><strong>Kardinalsymptome:</strong></p>
<ul>
<li>Schwere generalisierte Hypotonie</li>
<li>Okulohypische Krisen (charakteristisch!)</li>
<li>Temperaturinstabilit√§t</li>
<li>Hypersalivation und Schluckst√∂rungen</li>
<li>Ptosis und verminderte spontane Augenbewegungen</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Organsystem</th>
<th>Symptome/Befunde</th>
<th>Pathophysiologie</th>
<th>Schweregrad</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Bewegungsapparat</strong></td>
<td>Hypotonie, verz√∂gerte Motorik, Dystonie</td>
<td>Dopamin-Mangel im Striatum</td>
<td>+++</td>
</tr>
<tr>
<td><strong>Augen</strong></td>
<td>Ptosis, Okulohypische Krisen, Blickparese</td>
<td>Katecholamin-Mangel, zentral</td>
<td>+++</td>
</tr>
<tr>
<td><strong>Autonomes NS</strong></td>
<td>Temperaturinstabilit√§t, Hyperhidrose</td>
<td>Noradrenalin-Mangel</td>
<td>++</td>
</tr>
<tr>
<td><strong>GI-Trakt</strong></td>
<td>Hypersalivation, Gastro√∂sopha. Reflux</td>
<td>Serotonin-Mangel</td>
<td>++</td>
</tr>
<tr>
<td><strong>Schlaf/Verhalten</strong></td>
<td>Schlafst√∂rungen, Reizbarkeit</td>
<td>Serotonin-Mangel</td>
<td>++</td>
</tr>
<tr>
<td><strong>Entwicklung</strong></td>
<td>Schwere globale Retardierung</td>
<td>Beide NT-Systeme</td>
<td>+++</td>
</tr>
</tbody>
</table>

<div class="highlight-box">
<h4>üéØ Pathognomonische Zeichen bei AADC-Mangel</h4>

<p><strong>Okulohypische Krisen:</strong></p>
<ul>
<li>Unwillk√ºrliche, anhaltende Aufw√§rtsdeviation der Augen</li>
<li>K√∂nnen Stunden bis Tage andauern</li>
<li>Meist verbunden mit Opisthotonus</li>
<li>Verst√§rkt durch Stress, M√ºdigkeit oder Krankheit</li>
<li>Charakteristisch f√ºr AADC-Mangel!</li>
</ul>

<p><strong>Schwere neonatale Hypotonie:</strong></p>
<ul>
<li>"Floppy infant syndrome" ab Geburt</li>
<li>Schwache oder fehlende primitive Reflexe</li>
<li>Trinkschw√§che und Gedeihst√∂rung</li>
<li>Oft initial als SMA oder andere neuromuskul√§re Erkrankung fehlgedeutet</li>
</ul>
</div>

<div class="neuro-pathway">
<h4>üß† Langzeitfolgen ohne Behandlung</h4>
<ul>
<li><strong>Schwere intellektuelle Behinderung:</strong> IQ meist < 50</li>
<li><strong>Motorische Behinderung:</strong> Niemals freies Laufen</li>
<li><strong>Sprachentwicklung:</strong> Meist nur wenige Worte oder keine Sprache</li>
<li><strong>Epilepsie:</strong> Bei 20-30% der Patienten</li>
<li><strong>Lebenserwartung:</strong> Reduziert bei fehlender Behandlung</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Tyrosinhydroxylase-Mangel - Variable Ph√§notypen</h3>

<div class="pathway-diagram">
<h4>Drei klinische Formen</h4>

<div style="display: grid; grid-template-columns: repeat(auto-fit, minmax(250px, 1fr)); gap: 20px; margin: 20px 0;">

<div style="background: linear-gradient(135deg, #fef2f2, #fecaca); padding: 15px; border-radius: 8px; border: 2px solid #ef4444;">
<h5 style="color: #dc2626; margin-bottom: 10px;">üî¥ Typ A (schwer)</h5>
<ul style="font-size: 0.9em; color: #dc2626;">
<li>Neonatale Manifestation</li>
<li>Schwere generalisierte Dystonie</li>
<li>Hypokinetischer Parkinsonismus</li>
<li>Entwicklungsretardierung</li>
</ul>
</div>

<div style="background: linear-gradient(135deg, #fff7ed, #fed7aa); padding: 15px; border-radius: 8px; border: 2px solid #f97316;">
<h5 style="color: #ea580c; margin-bottom: 10px;">üü° Typ B (moderat)</h5>
<ul style="font-size: 0.9em; color: #ea580c;">
<li>Manifestation im Kindesalter</li>
<li>L-DOPA-responsive Dystonie</li>
<li>Normale Intelligenz</li>
<li>Fluktuation der Symptome</li>
</ul>
</div>

<div style="background: linear-gradient(135deg, #f0fdf4, #dcfce7); padding: 15px; border-radius: 8px; border: 2px solid #22c55e;">
<h5 style="color: #16a34a; margin-bottom: 10px;">üü¢ Segawa-√§hnlich</h5>
<ul style="font-size: 0.9em; color: #16a34a;">
<li>Sp√§te Kindheit/Adoleszenz</li>
<li>Fokale Dystonie der Beine</li>
<li>Diurnale Fluktuation</li>
<li>Exzellente L-DOPA-Response</li>
</ul>
</div>

</div>
</div>

<div class="case-study">
<h4>üîÑ Charakteristische Fluktuation</h4>

<p><strong>Tagesrhythmus:</strong></p>
<ul>
<li><strong>Morgens:</strong> Relativ gute Motorik nach Nachtruhe</li>
<li><strong>Nachmittags/Abends:</strong> Zunehmende Dystonie und Steifheit</li>
<li><strong>Stress/M√ºdigkeit:</strong> Akute Verschlechterung</li>
<li><strong>Fieber:</strong> Dramatische Symptomverst√§rkung</li>
</ul>

<p><strong>Typische Entwicklung der Symptome:</strong></p>
<ul>
<li><strong>S√§uglingsalter:</strong> Hypotonie, verz√∂gerte motorische Entwicklung</li>
<li><strong>Kleinkindalter:</strong> Beginn der Dystonie, meist an den Beinen</li>
<li><strong>Schulalter:</strong> Gangst√∂rungen, Schwierigkeiten beim Sport</li>
<li><strong>Adoleszenz:</strong> M√∂gliche Generalisierung der Dystonie</li>
</ul>

<p><strong>Unterscheidung zu anderen Dystonien:</strong></p>
<ul>
<li><strong>Fr√ºher Beginn:</strong> Meist vor dem 10. Lebensjahr</li>
<li><strong>Exzellente L-DOPA-Response:</strong> Oft dramatische Besserung</li>
<li><strong>Keine Progression:</strong> Stabil unter Therapie</li>
<li><strong>Famili√§re H√§ufung:</strong> Autosomal-rezessive Vererbung</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>Schweregrad</th>
<th>Manifestation</th>
<th>Hauptsymptome</th>
<th>L-DOPA Response</th>
<th>Prognose</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Schwer (Typ A)</strong></td>
<td>Neonatal/fr√ºh infantil</td>
<td>Generalisierte Dystonie, Parkinsonismus</td>
<td>Partial/unvollst√§ndig</td>
<td>Eingeschr√§nkt</td>
</tr>
<tr>
<td><strong>Moderat (Typ B)</strong></td>
<td>Sp√§te Kindheit</td>
<td>Dystonie der Extremit√§ten</td>
<td>Sehr gut</td>
<td>Gut</td>
</tr>
<tr>
<td><strong>Mild</strong></td>
<td>Adoleszenz/Erwachsenenalter</td>
<td>Fokale Dystonie</td>
<td>Exzellent</td>
<td>Exzellent</td>
</tr>
</tbody>
</table>
</div>

<div class="subsection">
<h3>BH4-Defekte - Heterogenes Spektrum</h3>

<div class="highlight-box">
<h4>üîó Gemeinsame Grundz√ºge aller BH4-Defekte</h4>

<p><strong>Neugeborenenscreening-Auff√§lligkeit:</strong></p>
<ul>
<li><strong>Erh√∂htes Phenylalanin</strong> (wie bei PKU)</li>
<li><strong>Aber:</strong> Zus√§tzliche neurologische Symptome</li>
<li><strong>Cave:</strong> BH4-Defekte werden oft als "atypische PKU" verkannt</li>
</ul>

<p><strong>Neurologische Progression:</strong></p>
<ul>
<li><strong>Initial:</strong> Oft normaler Neugeborenen-Befund</li>
<li><strong>2.-6. Monat:</strong> Beginn der neurologischen Symptome</li>
<li><strong>Ohne Behandlung:</strong> Progressive Verschlechterung</li>
</ul>
</div>

<table class="clinical-table">
<thead>
<tr>
<th>BH4-Defekt</th>
<th>H√§ufigkeit</th>
<th>Phenylalanin</th>
<th>Neurologische Symptome</th>
<th>Besonderheiten</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PTPS-Mangel</strong></td>
<td>60% aller BH4-Defekte</td>
<td>++</td>
<td>+++</td>
<td>Variable Schwere</td>
</tr>
<tr>
<td><strong>DHPR-Mangel</strong></td>
<td>25%</td>
<td>++</td>
<td>+++</td>
<td>Schwerste Form</td>
</tr>
<tr>
<td><strong>GTP-CH-I</strong></td>
<td>10%</td>
<td>++</td>
<td>+++</td>
<td>Auch dominant (DYT5)</td>
</tr>
<tr>
<td><strong>PCD-Mangel</strong></td>
<td>3%</td>
<td>+</td>
<td>++</td>
<td>Mildere Verl√§ufe</td>
</tr>
<tr>
<td><strong>SR-Mangel</strong></td>
<td>2%</td>
<td>-</td>
<td>++</td>
<td>Kein Phenylalanin ‚Üë</td>
</tr>
</tbody>
</table>

<div class="case-study">
<h4>üé≠ Spezifische Ph√§notypen der BH4-Defekte</h4>

<p><strong>PTPS-Mangel (h√§ufigste Form):</strong></p>
<ul>
<li><strong>Variabilit√§t:</strong> Von milden bis schweren Verl√§ufen</li>
<li><strong>Typische Trias:</strong> Hypotonie, Dystonie, intellektuelle Behinderung</li>
<li><strong>Zusatzsymptome:</strong> Temperaturinstabilit√§t, Hypersalivation</li>
<li><strong>Response:</strong> Gute Besserung unter BH4 + NT-Vorstufen</li>
</ul>

<p><strong>DHPR-Mangel (schwerste Form):</strong></p>
<ul>
<li><strong>Progressive Enzephalopathie:</strong> Trotz Phenylalanin-Kontrolle</li>
<li><strong>Zus√§tzlich:</strong> Fols√§ure-Mangel-Symptome</li>
<li><strong>Neurologisch:</strong> Spastik, Epilepsie, schwere Retardierung</li>
<li><strong>Therapie-Resistenz:</strong> Oft unvollst√§ndige Response</li>
</ul>

<p><strong>GTP-CH-I-Mangel:</strong></p>
<ul>
<li><strong>Rezessive Form:</strong> Schwere neonatale Pr√§sentation</li>
<li><strong>Dominante Form (DYT5):</strong> Segawa-Syndrom</li>
<li><strong>Diurnale Fluktuation:</strong> Besonders ausgepr√§gt</li>
<li><strong>Geschlechts-Bias:</strong> Dominante Form: Frauen > M√§nner</li>
</ul>

<p><strong>Sepiapterin-Reduktase-Mangel:</strong></p>
<ul>
<li><strong>Besonderheit:</strong> Normales Phenylalanin</li>
<li><strong>Hauptsymptom:</strong> L-DOPA-responsive Dystonie</li>
<li><strong>Serotonin intakt:</strong> Weniger Verhaltensauff√§lligkeiten</li>
<li><strong>Prognose:</strong> Relativ g√ºnstig bei fr√ºher Behandlung</li>
</ul>
</div>

<div class="neuro-pathway">
<h4>‚ö° Neurologische Progression bei BH4-Defekten</h4>

<p><strong>Fr√ºhe Phase (0-6 Monate):</strong></p>
<ul>
<li>Oft zun√§chst unauff√§llige neurologische Entwicklung</li>
<li>Phenylalanin-Erh√∂hung im Neugeborenenscreening</li>
<li>Erste Zeichen: Trinkschw√§che, Hypotonie</li>
</ul>

<p><strong>Mittlere Phase (6-24 Monate):</strong></p>
<ul>
<li>Beginn der charakteristischen neurologischen Symptome</li>
<li>Verz√∂gerte psychomotorische Entwicklung</li>
<li>Auftreten von Bewegungsst√∂rungen</li>
</ul>

<p><strong>Sp√§te Phase (> 2 Jahre):</strong></p>
<ul>
<li>Manifestation der vollen Symptombreite</li>
<li>Bei DHPR: Zus√§tzliche progressive Komponente</li>
<li>Ohne Behandlung: Schwere Behinderung</li>
</ul>
</div>
</div>

<div class="subsection">
<h3>Differentialdiagnose und Abgrenzung</h3>

<table class="clinical-table">
<thead>
<tr>
<th>Differentialdiagnose</th>
<th>Abgrenzung</th>
<th>Wichtige Unterschiede</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Zerebralparese</strong></td>
<td>Statisch vs. progressiv</td>
<td>NT-Defekte: Progressive Verschlechterung</td>
</tr>
<tr>
<td><strong>SMA/Muskeldystrophie</strong></td>
<td>Zentral vs. peripher</td>
<td>NT-Defekte: Normale EMG/NLG</td>
</tr>
<tr>
<td><strong>Mitochondriopathie</strong></td>
<td>Biomarker</td>
<td>NT-Defekte: Spezifische Metabolite</td>
</tr>
<tr>
<td><strong>Klassische PKU</strong></td>
<td>Neurologische Symptome</td>
<td>PKU: Keine fr√ºhe Neurologie bei Di√§t</td>
</tr>
<tr>
<td><strong>Anderen Dystonien</strong></td>
<td>L-DOPA-Response</td>
<td>NT-Defekte: Exzellente Response</td>
</tr>
<tr>
<td><strong>Epilepsie-Syndrome</strong></td>
<td>EEG und Response</td>
<td>NT-Defekte: Antikonvulsiva wenig wirksam</td>
</tr>
</tbody>
</table>

<div class="case-study">
<h4>üö® Red Flags f√ºr Neurotransmitter-Defekte</h4>

<p><strong>Bei S√§uglingen:</strong></p>
<ul>
<li><strong>Kombiniert:</strong> Hypotonie + Bewegungsst√∂rungen</li>
<li><strong>Temperaturinstabilit√§t</strong> ohne Infektionszeichen</li>
<li><strong>Okulohypische Krisen</strong> (pathognomonisch f√ºr AADC)</li>
<li><strong>Erh√∂htes Phenylalanin + Neurologie</strong> (BH4-Defekte)</li>
</ul>

<p><strong>Bei √§lteren Kindern:</strong></p>
<ul>
<li><strong>L-DOPA-responsive Dystonie</strong> mit fr√ºhem Beginn</li>
<li><strong>Diurnale Fluktuation</strong> der Bewegungsst√∂rungen</li>
<li><strong>Famili√§re H√§ufung</strong> √§hnlicher Symptome</li>
<li><strong>Fieber-induzierte Verschlechterung</strong></li>
</ul>

<p><strong>Anamnestische Hinweise:</strong></p>
<ul>
<li><strong>Konsanguinit√§t der Eltern</strong> (erh√∂htes Risiko)</li>
<li><strong>Fr√ºher Kindstod</strong> in der Familie</li>
<li><strong>√Ñhnliche Symptome bei Geschwistern</strong></li>
<li><strong>Therapie-refrakt√§re "Epilepsie"</strong></li>
</ul>
</div>
</div>

<div class="next-step">
<div style="text-align: center; margin-top: 2rem; padding: 2rem; background: linear-gradient(135deg, #eff6ff, #dbeafe); border-radius: var(--border-radius); border: 2px solid var(--info-color);">
<h3 style="color: var(--info-color); margin-bottom: 1rem;">üéâ Teil 1 abgeschlossen!</h3>
<p style="color: var(--text-secondary); margin-bottom: 1.5rem;">Sie haben die Grundlagen, Biochemie und klinischen Pr√§sentationen erfolgreich durchgearbeitet.</p>
<p style="color: var(--text-secondary); margin-bottom: 1.5rem;"><strong>Als n√§chstes:</strong> Teil 2 mit Diagnostik und Therapie</p>
<button class="next-btn">Weiter zu Teil 2 ‚Üí</button>
</div>
</div>
</div>

</div>

<script>
let currentSection = 0;
const sections = ['grundlagen', 'biochemie', 'klinik'];

function showSection(sectionId) {
// Hide all sections
const allSections = document.querySelectorAll('.content-section');
allSections.forEach(section => section.classList.remove('active'));

// Remove active class from all nav buttons
const allButtons = document.querySelectorAll('.nav-btn');
allButtons.forEach(btn => btn.classList.remove('active'));

// Show selected section
document.getElementById(sectionId).classList.add('active');

// Highlight active nav button
event.target.classList.add('active');

// Update progress bar
currentSection = sections.indexOf(sectionId);
const progress = ((currentSection + 1) / sections.length) * 100;
document.getElementById('progressBar').style.width = progress + '%';

// Scroll to top
window.scrollTo(0, 0);
}

// Initialize progress bar
document.getElementById('progressBar').style.width = '33.3%';
</script>

</body>
</html>
